Palisade Bio (PALI) Competitors $0.60 +0.02 (+2.75%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.60 +0.00 (+0.17%) As of 09/12/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. ASBP, FNCH, CING, CTXR, LEXX, HOTH, LSTA, TLPH, SYBX, and EDSAShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Aspire Biopharma (ASBP), Finch Therapeutics Group (FNCH), Cingulate (CING), Citius Pharmaceuticals (CTXR), Lexaria Bioscience (LEXX), Hoth Therapeutics (HOTH), Lisata Therapeutics (LSTA), Talphera (TLPH), Synlogic (SYBX), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Its Competitors Aspire Biopharma Finch Therapeutics Group Cingulate Citius Pharmaceuticals Lexaria Bioscience Hoth Therapeutics Lisata Therapeutics Talphera Synlogic Edesa Biotech Aspire Biopharma (NASDAQ:ASBP) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Is ASBP or PALI more profitable? Aspire Biopharma's return on equity of 0.00% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Aspire BiopharmaN/A N/A -737.96% Palisade Bio N/A -214.94%-135.09% Does the media prefer ASBP or PALI? In the previous week, Palisade Bio had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for Palisade Bio and 1 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 1.89 beat Palisade Bio's score of 1.02 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Overall Sentiment Aspire Biopharma Very Positive Palisade Bio Positive Do analysts prefer ASBP or PALI? Palisade Bio has a consensus target price of $12.00, indicating a potential upside of 1,906.69%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Aspire Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ASBP or PALI? Aspire Biopharma has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Which has better valuation & earnings, ASBP or PALI? Aspire Biopharma has higher earnings, but lower revenue than Palisade Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAspire BiopharmaN/AN/A-$12.54MN/AN/APalisade Bio$250K21.82-$14.44M-$4.06-0.15 Do institutionals & insiders believe in ASBP or PALI? 19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 48.0% of Aspire Biopharma shares are held by insiders. Comparatively, 0.7% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryPalisade Bio beats Aspire Biopharma on 7 of the 12 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.45M$3.16B$5.79B$10.19BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-0.1521.4375.4026.02Price / Sales21.82418.25530.60120.19Price / CashN/A44.4425.8129.91Price / Book0.229.6112.166.25Net Income-$14.44M-$53.29M$3.29B$270.76M7 Day Performance-4.55%0.13%0.74%3.87%1 Month Performance-26.63%5.55%5.00%5.49%1 Year Performance-84.22%10.44%62.55%25.86% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio3.1549 of 5 stars$0.60+2.7%$12.00+1,906.7%-84.2%$5.45M$250K-0.1510Positive NewsShort Interest ↓Gap DownASBPAspire BiopharmaN/A$0.41-19.5%N/AN/A$20.40MN/A0.00N/APositive NewsFNCHFinch Therapeutics Group1.4074 of 5 stars$12.70flatN/A+9.7%$20.40MN/A-1.44190Negative NewsShort Interest ↓CINGCingulate2.9636 of 5 stars$3.73-0.7%$26.25+604.7%-26.9%$20.15MN/A-0.9120Positive NewsCTXRCitius Pharmaceuticals2.5025 of 5 stars$1.18-3.7%$53.00+4,410.6%-90.7%$19.99MN/A0.0020News CoverageAnalyst UpgradeShort Interest ↑LEXXLexaria Bioscience3.8869 of 5 stars$1.01-2.9%$4.00+296.0%-65.3%$19.76M$460K-1.517Positive NewsShort Interest ↓HOTHHoth Therapeutics2.8248 of 5 stars$1.47flat$4.00+172.1%+45.5%$19.56MN/A-1.384Analyst UpgradeShort Interest ↓Gap UpLSTALisata Therapeutics3.2387 of 5 stars$2.18flat$23.50+978.0%-24.7%$19.10M$1M-0.9830Short Interest ↓TLPHTalphera2.015 of 5 stars$0.91+10.7%$5.00+451.3%+4.4%$18.61M$27K-2.2719Short Interest ↑Gap UpHigh Trading VolumeSYBXSynlogic1.6384 of 5 stars$1.48+0.7%N/A+13.6%$17.32M$10K-18.5080Positive NewsShort Interest ↓Gap UpEDSAEdesa Biotech1.448 of 5 stars$2.44+0.8%$5.00+104.9%-43.9%$17.18MN/A-1.8520 Related Companies and Tools Related Companies ASBP Alternatives FNCH Alternatives CING Alternatives CTXR Alternatives LEXX Alternatives HOTH Alternatives LSTA Alternatives TLPH Alternatives SYBX Alternatives EDSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PALI Stock Alerts